Patients with Alpha-1 Antitrypsin Deficiency
Tóm tắt
Alpha-1 antitrypsin (AAT) deficiency is a genetic disorder that leads to decreased circulating levels of AAT, which significantly increases the risk of serious lung and liver disease. Although previously considered to be limited to people of northern European ancestry, it is now known that people all over the world are affected. Over 100 abnormal alleles have been identified — the most common disease-producing of these being ‘S’ and ‘Z’. AAT deficiency is often beneath the diagnostic radar; consequently, it is typically unrecognized until the appearance of advanced lung or liver disease. It is important to detect AAT deficiency prior to the development of severe lung disease, since early augmentation therapy may limit the decline in function. Patients should be guided to immediately discontinue smoking and avoid smoke-filled environments, to keep away from other lung irritants, improve nutritional practices, participate in daily exercise, use preventive medical practices to limit disease, and become knowledgeable about the disease process and signs and symptoms of exacerbations. An aggressive disease management process should be initiated and continually refined for the individual patient. Disease management is a collaborative arrangement between patient and physician. The self-management component is a set of skills and routines to enable the patient to maximize disease control at home and recognize the earliest signs and symptoms of an exacerbation. A daily exercise program such as walking is essential on many levels. With continued research and ongoing clinical trials, patients with AAT deficiency will be provided with improved alternatives for managing their disease and perhaps an eventual cure. For the time being, aggressive preventive and disease management practices offer the best solution.
Tài liệu tham khảo
Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): the European Respiratory Society Task Force. Eur Respir J 2007; 8: 1398–420
Asia Pacific COPD Roundtable Group. Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective. Respirology 2005; 10(1): 9–17
Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initative for Chronic Obstructive Pulmonary Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256–76
Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613–20
Buist AS, Vollmer WM, Sullivan SD, et al. The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD 2005; 2(2): 277–83
Joint Statement of the ATS/ERS societies. ATS/ERS statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168: 818–900
Sveger T. Liver disease in alpha-1-antitrypsin deficiency detected by screening of 200 000 infants. N Engl J Med 1976; 294: 1316–21
de Serres FJ. Worldwide racial and ethnic distribution of alpha-1-antitrypsin deficiency: details of an analysis of published genetic epidemiologic surveys. Chest 2002; 122: 1818–29
de Serres FJ, Blanco I, Bustillo EF. Genetic epidemiology of alpha-1-antitrypsin deficiency: France, Italy, Portugal and Spain. Clin Genet 2003; 63: 490–509
Sigsgaard T, Brandslund I, Omland O, et al. S and Z alpha 1-antitrypsin alleles are risk factors for bronchial hyperresponsiveness in young farm workers: an example of gene/environment interaction. Eur Respir J 2000; 16: 50–5
Mayer AS, Stroller JK, Bucher-Bartelson BL, et al. Occupational exposure risk in individuals with PiZ Alpha 1-antrypsin deficiency. Am J Respir Crit Care Med 2000; 162: 553–8
WHO. AAT deficiency. Geneva: WHO, 1996
Pierce JA. Antitrypsin and emphysema: perspective and prospects. JAMA 1988; 259: 2890–5
Hubbard RC, Crystal R. Augmentation therapy for alpha 1-antrypsin deficiency. Eur Respir J 1990; 3 Suppl. 9: 44s–52s
Bazex J, Bayle P. Alpha 1-antrypsin deficiency: cutaneous aspects. Bull Acad Natl Med 2002; 186: 1479–87
O’Riordan K, Blei A, Rao MS, et al. Alpha 1-antrypsin deficiency-associated Panniculitis: resolution with intravenous alpha 1-antitrypsin administration and liver transplantation. Transplantation 1997; 63: 480–2
Tservistas M, Bitterle E, Keller M, et al. Aerosol characterization of α-1 antitrypsin after nebulization with eFlow®, a novel vibrating membrane nebulizer P2515 [poster 2515]. European Respiratory Society Congress; 2006 Sep 2–6; Munich [online]. Available from URL: https://www.ersnetsecure.org/public/prg_congres.abstract?ww_i_presentation=25602 [Accessed 2008 Oct 10]
Alpha-1 Committee. Alpha-1 disease management and prevention program. Gainsville (FL): Alpha Net Inc., 2004
Hay JW, Robin ED. Cost effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive disease. Am J Public Health 1991; 81: 427–33
The Alpha-1-Antrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alphal -antitrypsin. Am J Respir Crit Care Med 1998; 158: 49–59
Alkins SA, O’Malley P. Should health-care systems pay for replacement therapy in patients with alphal-antitrypsin deficiency? A critical review and cost-effectiveness analysis. Chest 2000; 117: 875–80
Alkins SA, O’Malley P. Should health-care systems pay for replacement therapy in patients with alpha-1-antitrypsin deficiency? Chest 2000; 117(3): 875–80
Stroller JK, Gildea TR, Shermock KM, et al. Cost-effectiveness of population screening for alpha-1 antitrypsin deficiency: a decision analysis. COPD 2005 Dec; 2(4): 411–8
Alpha-1 Foundation [online]. Available from URL: http://www.alphaone.org/ [Accessed 2008 Oct 3]
Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93(3): 391–8
Emtner M, Porszasz J, Burns M, et al. Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. Am J Respir Crit Care Med 2003; 168(9): 1034–42
ATS. ATS guidelines: sleep apnea; sleepiness; and driving risk. UpToDate, 2007 [online]. Available from URL: http://www.uptodate.com/home/index.html [Accessed 2008 Oct 10]
Mechanick JI, Brett EM. Nutrition and the chronically critically ill patient. Curr Opin Clin Nutr Metab Care 2005; 8(1): 33–9
Shankar P, McMillan J, Carter R. Nutritional support, body weight and Chronic Obstructive Pulmonary Disease (COPD): part I. RT: The Journal for Respiratory Care Practitioners 2004; 31-41 [online]. Available from URL: http://www.rtmagazine.com/issues/articles/2004-05_05.asp [Accessed 2008 Oct 10]
Brag J, Schols A, Mesters I. Dietary change, nutrition education and chronic obstructive pulmonary disease. Patient Educ Couns 2004; 52(3): 249–57
Cochrane WJ, Afolabi OA. Investigation into the nutritional status, dietary intake and smoking habits of patients with chronic obstructive pulmonary disease. J Hum Nutr Diet 2004; 17(1): 3–11
Casaburi R. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Med Sci Sports Exerc 2001; 33 (7 Suppl.): S662–70
Wouters EFM. Nutrition and metabolism in COPD. Chest 2000; 117(5): 274S–80S
Piitulainen E, Areberg J, Linden M, et al. Nutritional status and muscle strength in patients with emphysema and severe alpha-1 antitrypsin deficiency. Chest 2002; 122: 1240–6
Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss: a longitudional study of alternative day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983; 25: 615–20
Carter R, Nicotra B, Sanfelippo P. Reversing pathophysiologic changes of chronic obstructive pulmonary disease with lung volume reduction surgery and exercise rehabilitation. Clin Pulm Med 1996; 3(5): 237–48
Carter R, Nicotra B. Newer insights into the management and rehabilitation of the patient with pulmonary disease. Sem Res Med 1986; 8: 113–23
ERS-ATS task force. ERS-ATS standards for the diagnosis and management of patients with COPD. Eur Respir J 2004; 23: 932–46
Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008; 31(1): 12–20
Schouten JA, Hulscher ME, Trap-Liefers J, et al. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a clusterrandomized, controlled trial. Clin Infect Dis 2007; 44(7): 931–41
Siempos II, Dimopoulos G, Korbila IP, et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; 29(6): 1127–37
Blasi F, Cazzola M, Tarsia P, et al. Telithromycin in lower respiratory tract infections. Future Microbiol 2006; 1: 7–16
Querol-Ribelles JM, Molina J, Naberan K, et al. Discrepancy between antibiotics administered in acute exacerbations of chronic bronchitis and susceptibility of isolated pathogens in respiratory samples: multicentre study in the primary care setting. Int J Antimicrob Agents 2006; 28(5): 472–6
Watz H, Bitter-Suermann S, Kanniess F, et al. Pharmacological treatment of COPD and future of anti-inflammatory therapy [in German]. Med Klin (Munich) 2006; 101(4): 283–92
Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006; 290(1): L75–85
Martinez FJ, Simon RH. Clinical implications of macrolide therapy in chronic sinopulmonary diseases. Curr Pharm Des 2004; 10(25): 3095–110
Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004; 125 (2 Suppl.): 52S–60S
Swords WE, Rubin BK. Macrolide antibiotics, bacterial populations and inflammatory airway disease. Neth J Med 2003; 61(7): 242–8
American Thoracic Society/European Respiratory Society Task Force. Standards for the diagnosis and management of patients with COPD: version 1.2. New York: American Thoracic Society, 2004 (updated 2005 Sep 8) [online]. Available from URL: http://www.thoracic.org/go/copd [Accessed 2008 Oct 10]
Tiep BL, Carter R. Long-term oxygen therapy. In: Donner C, Ambrosino N, Goldstein R, editors. Pulmonary rehabilitation. London: Hodder Arnold, 2006: 312–20
Tiep BL, Carter R. Long-term supplemental oxygen therapy. UpToDate 2006 [online]. Available from URL: http://www.uptodate.com/home/index.html [Accessed 2008 Oct 10]